Wendy K. Nevala

Mayo Clinic — United States

Medicine · Health Sciences

28h-index3.3kcitations190works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(62), Immunotherapy and Immune Responses(57), Cancer Immunotherapy and Biomarkers(41), Phagocytosis and Immune Regulation(30), Monoclonal and Polyclonal Antibodies Research(21)

Publications190 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Proteomic Analysis of Small Extracellular Vesicles From Lymphatic Affluents in Developing Premetastatic Niche in Melanoma
Molecular & Cellular Proteomics·2025Open Access
Spatial Multiplexed Immunofluorescence Imaging Exploring The Tumor Immune Microenvironment of Melanoma
2025
Proteomic analysis of exosomes from lymphatic affluents reveals their implications in developing premetastatic niche in melanoma
2025Open Access
Abstract 1578 TMT-based quantitative proteomic analysis of lymphatic exosomes reveals pathways involved in sentinel lymph node remodeling in melanoma
Journal of Biological Chemistry·2025Open Access
PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model
International Journal of Molecular Sciences·2025· 1 citedOpen Access
Melanoma-derived cytokines and extracellular vesicles are interlinked with macrophage immunosuppression
Frontiers in Molecular Biosciences·2025· 1 citedOpen Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Melanoma-Derived Extracellular Vesicles Induce CD36-Mediated Pre-Metastatic Niche
Biomolecules·2024· 4 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Svetomir N. Markovic(39), Alexey A. Leontovich(10), Aaron S. Mansfield(9), Roxana Dronca(9), Elizabeth Ann L. Enninga(8), Vera J. Suman(8), Michael A. Thompson(7), Lisa A. Kottschade(7), Matthew S. Block(7), Shernan G. Holtan(6), Haidong Dong(6), Robert R. McWilliams(6), Reona Sakemura(5), Mehrdad Hefazi(5), Neil E. Kay(5), Saad S. Kenderian(5), Lionel Aurelien Kankeu Fonkoua(5), Edward T. Creagan(5), Michelle J. Cox(4), Michael J. Hansen(4)